Pet nutrition product supplier Nourse and Chengdu MaxHealth Biotechnology have secured funding.
Temasek-backed Vertex backs Nourse’s Series B++
Chinese pet nutrition product supplier Nourse has completed its Series B++ round of financing raising over 200 million yuan ($30 million) from existing investors such as Vertex Ventures China, per a company statement on Wednesday.
The company has raised a total of 900 million yuan ($139 million) in three tranches of its Series B round. Its Series B tranches have been backed by investors including Hony Capital, Meridian Capital China, Tencent Investment, Cathay Capital and Highlight Capital.
Founded by Shaohua Lv in 2004, Nourse produces special dietary supplements for dogs and cats. It has built competitive online channels on Tmall and JD.com for its pipeline of 21 products.
KIP backs MaxHealth Biotechnology
Chengdu MaxHealth Biotechnology LLC, a clinical-stage firm focused on vaccine R&D, has received ‘tens of millions of US dollars’ in its Series A round of financing, according to a company statement on Wednesday.
Existing investors – Korea Investment Partners (KIP), Hillhouse Capital’s venture unit GL Ventures and Sherpa Healthcare Partners – participated in the latest round. The three investors had partnered for MaxHealth’s Pre-A round as well.
MaxHealth, founded by Dr. Dexiang Chen in 2017, has rolled out 10 vaccine pipelines that cater to treatment areas targeting infectious diseases, allergies and cancers.